Lung Cancer | Optimizing Biomarker-Based Decision-Making for Patients with Non-Small Cell Lung Cancer with EGFR Mutations or with Other Oncogene-Addicted Lung Cancers — Session 2
Free with Audible trial. Cancel anytime.
Quick Facts
| Author | Unknown |
| Narrator | Unknown |
| Runtime | 0h57m |
| Published | January 7, 2022 |
| Rating | 4.5 / 5 (15 ratings) |
| Categories | Health & Wellness, Physical Illness & Disease, Hygiene & Healthy Living, Science & Engineering, Science |
| Format | Audiobook (Digital) |
| Platform | Audible |
Featured Audiobooks
Handpicked listeners' favorites this week
About This Audiobook
Featuring perspectives from Drs Marc Ladanyi, Andrew McKenzie and Helena Yu, including the following topics: Introduction: Role of Genomic Profiling ...
Why Listen to Lung Cancer | Optimizing Biomarker-Based Decision-Making for Patients with Non-Small Cell Lung Cancer with EGFR Mutations or with Other Oncogene-Addicted Lung Cancers — Session 2?
- Expert narration by Unknown brings every character and scene to life across 0h57m of immersive audio.
- Bestseller-quality story from Unknown, rated 4.5 stars by 15 listeners.
- Free with your Audible trial — keep the audiobook forever even if you cancel.
- Perfect for commutes, workouts, and relaxation. Listen anywhere, anytime.
Download: Lung Cancer | Optimizing Biomarker-Based Decision-Making for Patients with Non-Small Cell Lung Cancer with EGFR Mutations or with Other Oncogene-Addicted Lung Cancers — Session 2
Some links on this page are affiliate links. If you make a purchase through one of them, we may earn a small commission at no extra cost to you.
Lung Cancer | Optimizing Biomarker-Based Decision-Making for Patients with Non-Small Cell Lung Cancer with EGFR Mutations or with Other Oncogene-Addicted Lung Cancers — Session 2 by Unknown is an immersive listening experience. Performed by Unknown with a runtime of 0h57m, you can start with a free trial that you can cancel at any time. The audiobook remains yours forever, even if you end the trial.